Q-omics provides the consensus-scored ZNF333 profile across patient tissues and cancer cell-line models. ZNF333 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF333 is differentially expressed in 11, with the highest sampling consensus in UCEC. Additionally, ZNF333 RNA expression shows 21,186 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, UCEC, and THYM as cancer lineages where ZNF333 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF333 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF333 survival associations across molecular data types. ZNF333 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF333 RNA expression–survival associations across cancer types. High ZNF333 expression shows unfavorable associations in KICH, ACC and KIRC, but favorable associations in HNSC, UCS and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF333 RNA expression.
This table summarizes ZNF333 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF333. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF333 shows lower tumor expression in UCEC, THCA, LUAD and BRCA and higher tumor expression in LIHC and KIRC. The UCEC box plot shows higher ZNF333 RNA expression in normal versus tumor tissue (log2 FC = −1.550, t-test p < 0.001).
This table shows molecular features associated with ZNF333 in patient tissues and cancer cell lines. In patient samples, ZNF333 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF333 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and UPPER_AERODIGESTIVE_TRACT.
